sumatriptan has been researched along with Cicatrization in 1 studies
Sumatriptan: A serotonin agonist that acts selectively at 5HT1 receptors. It is used in the treatment of MIGRAINE DISORDERS.
sumatriptan : A sulfonamide that consists of N,N-dimethyltryptamine bearing an additional (N-methylsulfamoyl)methyl substituent at position 5. Selective agonist for a vascular 5-HT1 receptor subtype (probably a member of the 5-HT1D family). Used (in the form of its succinate salt) for the acute treatment of migraine with or without aura in adults.
Cicatrization: The formation of fibrous tissue in the place of normal tissue during the process of WOUND HEALING. It includes scar tissue formation occurring in healing internal organs as well as in the skin after surface injuries.
| Excerpt | Relevance | Reference |
|---|---|---|
| " As of 2018, the FDA Adverse Event Reporting System public dashboard lists a total of 2889 reports of safety problems with the patch, 904 of which were classified as serious." | 1.48 | Safety Problems With a Transdermal Patch for Migraine: Lessons From the Development, Approval, and Marketing Process. ( Burch, RC; Loder, EW; Rayhill, M, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Loder, EW | 1 |
| Rayhill, M | 1 |
| Burch, RC | 1 |
1 other study available for sumatriptan and Cicatrization
| Article | Year |
|---|---|
Safety Problems With a Transdermal Patch for Migraine: Lessons From the Development, Approval, and Marketing Process.
Topics: Adverse Drug Reaction Reporting Systems; Burns, Chemical; Cicatrix; Clinical Trials as Topic; Drug A | 2018 |